Search

Your search keyword '"Bette Korber"' showing total 94 results

Search Constraints

Start Over You searched for: Author "Bette Korber" Remove constraint Author: "Bette Korber"
94 results on '"Bette Korber"'

Search Results

1. Engineering immunogens that select for specific mutations in HIV broadly neutralizing antibodies

2. Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control studyResearch in context

3. Design, Immunogenicity and Preclinical Efficacy of the ChAdOx1.COVconsv12 Pan-Sarbecovirus T-Cell Vaccine

4. Structural basis for breadth development in the HIV-1 V3-glycan targeting DH270 antibody clonal lineage

5. US National Institutes of Health Prioritization of SARS-CoV-2 Variants

6. Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates

7. Immunogenicity and protective efficacy of a rhesus adenoviral vaccine targeting conserved COVID-19 replication transcription complex

8. Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials.

9. Efficacy of antivirals and mRNA vaccination against an XBF clinical isolate

10. SARS-CoV-2 variant transition dynamics are associated with vaccination rates, number of co-circulating variants, and convalescent immunityResearch in context

11. Network analysis uncovers the communication structure of SARS-CoV-2 spike protein identifying sites for immunogen design

12. Effect of epitope variant co-delivery on the depth of CD8 T cell responses induced by HIV-1 conserved mosaic vaccines

13. Epigraph hemagglutinin vaccine induces broad cross-reactive immunity against swine H3 influenza virus

14. T cell-based strategies for HIV-1 vaccines

15. Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates.

16. Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations

17. Estimating the Timing of Early Simian-Human Immunodeficiency Virus Infections: a Comparison between Poisson Fitter and BEAST

18. Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection

19. Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates

20. Complete protection of the BALB/c and C57BL/6J mice against Ebola and Marburg virus lethal challenges by pan-filovirus T-cell epigraph vaccine.

21. Exploring the Role of Glycans in the Interaction of SARS-CoV-2 RBD and Human Receptor ACE2

22. Tetravalent Immunogen Assembled from Conserved Regions of HIV-1 and Delivered as mRNA Demonstrates Potent Preclinical T-Cell Immunogenicity and Breadth

23. Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth

24. Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections.

25. A single, continuous metric to define tiered serum neutralization potency against HIV

26. Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants

27. Correction: Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization.

28. Effect of Glycosylation on an Immunodominant Region in the V1V2 Variable Domain of the HIV-1 Envelope gp120 Protein.

29. Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization.

30. Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection.

31. Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial.

32. A mechanistic understanding of allosteric immune escape pathways in the HIV-1 envelope glycoprotein.

33. Designing and testing broadly-protective filoviral vaccines optimized for cytotoxic T-lymphocyte epitope coverage.

34. Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections.

35. Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infection.

37. Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies.

38. HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC.

39. Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo.

41. Design and pre-clinical evaluation of a universal HIV-1 vaccine.

42. Immunoinformatics comes of age.

43. SARS-CoV-2 variant transition dynamics are associated with vaccination rates, number of co-circulating variants, and natural immunity

44. Substantial Neutralization Escape by the SARS-CoV-2 Omicron Variant BQ.1.1

45. Multiple lineages of monkeypox virus detected in the United States, 2021-2022

46. Structural basis for breadth development in a HIV-1 neutralizing antibody

47. Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates

48. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies

50. Characterization of the SARS-CoV-2 B.1.621 (Mu) variant

Catalog

Books, media, physical & digital resources